Search the Newsreel

CRISPR Therapeutics AG (CRSP) Financial Health: Profitability & Balance Sheet Analysis

CRISPR Therapeutics AG (CRSP) has a weak financial status with a current financial score of 6.45, ranking 242 out of 384 in its industry. Despite a 68.55% year-over-year revenue increase to $1.46M and a 9.61% net profit increase, its operating efficiency is low. The …

Morgan Stanley Nearly Doubled Its Price Target for CRISPR Therapeutics. Is the Gene-Editing Stock a No-Brainer Buy?

Key Points CRISPR Therapeutics recently won a key label expansion. The company has important data readouts on the horizon. The stock is somewhat risky given the possibility of clinical failures. 10 stocks we like better than CRISPR Therapeutics › CRISPR Therapeutics(NASDAQ: CRSP) has had …

CRISPR Therapeutics AG (CRSP) Exceeds Market Returns: Some Facts to Consider

CRISPR Therapeutics AG (CRSP) ended the recent trading session at $48.44, demonstrating a +1.68% change from the preceding day's closing price. The stock's change was more than the S&P 500's daily gain of 1.66%. Elsewhere, the Dow saw an upswing of 1.19%, while the …

How Crispr Therapeutics Ag (CRSP) Affects Rotational Strategy Timing

This article analyzes Crispr Therapeutics Ag (NASDAQ: CRSP) using AI models to provide trading strategies. It highlights weak sentiment across all horizons, suggesting a short bias, and details position, momentum breakout, and risk hedging strategies with specific entry, target, and stop-loss levels. The analysis …

Price to earnings forward of CRISPR Therapeutics AG Shs Thailand Depositary Receipts Repr 1 Sh – SET:CRSP03

This article focuses on the "Price to earnings forward" metric for CRISPR Therapeutics AG Shs Thailand Depositary Receipts, traded on the Stock Exchange of Thailand under the symbol CRSP03. It's a financial data point from TradingView, indicating a specific period, value, and change for …

3 Mid-Cap Growth Stocks With Monstrous Long-Term Upside

Investing in stocks with modest valuations can set investors up for some significant returns in the long run. While there is more risk involved in putting money into smaller, less-established businesses, the upside can also be considerable, potentially resulting in massive gains. Three mid-cap …

CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know

CRISPR Therapeutics AG (CRSP) has garnered investor attention, appearing on Zacks.com's list of most searched stocks. Despite a recent share decline, the article highlights the importance of earnings estimate revisions, revenue growth potential, and valuation in assessing the stock's future. CRISPR Therapeutics currently holds …

ISPR|Ispire Technology Inc|Price:1.500|Chg%:-0.100

Ispire Technology Inc (ISPR) is trading at $1.50, down 6.25% today, with a market cap of $86.10M. Analysts rate the stock as a "Strong Buy" with a target price of $5.00, suggesting a significant upside. The company specializes in e-cigarettes and vaping hardware for …

Ispire Technology Inc (ISPR) Financial Health: Profitability & Balance Sheet Analysis

Ispire Technology Inc (ISPR) currently holds a financial score of 6.69, placing it 63rd out of 93 companies in the Food & Tobacco industry. The company's financial status is stable with high operating efficiency, despite a recent 28.66% year-over-year decrease in quarterly revenue and …

Ispire Technology Inc (ISPR) Institutional Confidence

Ispire Technology Inc (ISPR) has an institutional shareholding score of 3.00, placing it 55th out of 93 in the Food & Tobacco industry. The latest institutional shareholding proportion is 9.19%, an 8.42% increase quarter-over-quarter. ETHSX is the largest institutional shareholder, holding 66.13K shares, despite …

BlackRock (CRSP holder) discloses 7.99M-share, 8.3% stake in CRISPR Therapeutics

BlackRock, Inc. has filed an amended ownership report, disclosing a beneficial ownership of 7,987,262 shares, or an 8.3% stake, in CRISPR Therapeutics AG common stock. The filing, a SCHEDULE 13G/A, indicates that BlackRock holds sole voting power over 7,841,979 shares and sole dispositive power …

CRISPR Therapeutics AG (CRSP) Cash Flow

This article provides a detailed cash flow statement for CRISPR Therapeutics AG (CRSP), covering quarterly and annual data for operating, investing, and financing activities. It includes key financial metrics like operating cash flow, net income from continuing operations, capital expenditures, and free cash flow …

CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

CRISPR Therapeutics AG (CRSP) is anticipated to exceed earnings estimates for the quarter ending June 2026, with an expected year-over-year increase in earnings and a significant rise in revenues. The company's positive Earnings ESP of +1.94% combined with a Zacks Rank #3 suggests a …

Ispire Technology Inc (ISPR) Cash Flow

This article provides a detailed cash flow statement for Ispire Technology Inc (ISPR), breaking down its operating, investing, and financing cash flows on a quarterly and annual basis. It includes historical data and year-over-year changes for various cash flow components, along with definitions and …

Ispire Technology (NASDAQ:ISPR) Upgraded at BTIG Research

BTIG Research has upgraded Ispire Technology (NASDAQ:ISPR) to a "strong-buy" rating despite the company's recent weak quarterly results and a cautious "Hold" consensus rating from other analysts. The company missed earnings and revenue estimates, reporting a loss of $0.17 per share and $18.69 million …

CRISPR Therapeutics AG (CRSP) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for CRISPR Therapeutics AG (CRSP), noting its current earnings forecast score and industry ranking. It presents analyst ratings, target prices, and a peer comparison, along with expected EPS and revenue figures. The consensus among analysts is a "Buy" …

Ispire Technology Inc (ISPR) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Ispire Technology Inc (ISPR), highlighting its current valuation score of 9.35, which ranks 15th in the Food & Tobacco industry. The company's P/E ratio is noted at -2.59, and further valuation metrics like P/B, P/S, and P/CF …

Ispire Technology Inc (ISPR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Ispire Technology Inc (ISPR), detailing its regional revenue contributions. As of the latest available data, Europe accounts for the largest share at 72.88%, followed by Asia Pacific, North America, and other regions. Information regarding business segments and …

ISPR|Ispire Technology Inc|Price:1.650|Chg%:-0.080

Ispire Technology Inc (ISPR) is trading at $1.50, down 6.25% today, with a market cap of $86.10M. Analysts rate the stock as a "Strong Buy" with a target price of $5.00, suggesting a significant upside. The company specializes in e-cigarettes and vaping hardware for …

CRISPR Therapeutics (CRSP) Enters Phase 1 With CTX112 In Allogeneic CAR T

CRISPR Therapeutics (CRSP) has initiated Phase 1 clinical trials for its allogeneic CAR T candidate CTX112, targeting lymphoma and autoimmune diseases. This move expands the company's focus beyond gene editing, aiming to address critical issues of cost, manufacturing complexity, and access associated with current …

CRSP|CRISPR Therapeutics AG|Price:46.540|Chg%:-0.990

CRISPR Therapeutics AG (CRSP) is a Switzerland-based gene editing company with high growth potential, though its stock performance has been weak recently. The company's valuation is considered fair, and institutional ownership is very high. Analysts have rated it as a "Buy" with a significant …

CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know

CRISPR Therapeutics AG (CRSP) saw its stock decline by 2.08% to $46.54, underperforming a market where the S&P 500 gained marginally. The company's shares have dropped 11.95% over the last month, lagging behind the Medical sector. Analysts forecast an EPS of -$1.1 and revenue …

Ispire Technology Inc (ISPR) Risk Assessment: Volatility, Financial Risk & Investment Risk

Ispire Technology Inc (ISPR) has a current risk assessment score of 2.19, ranking 68 out of 93 in the Food & Tobacco industry. The company's beta value of 0.00 suggests it tends to underperform during rising markets but experiences smaller declines during downturns. Key …

CRISPR Therapeutics (CRSP) H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025 summary

CRISPR Therapeutics (CRSP) presented at the H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025, detailing strategic partnerships, pipeline progress, and financial outlook. Key highlights include a co-development deal with Sirius Therapeutics for an siRNA platform, ongoing commercialization success of Casgevy, and promising Phase I …

CRISPR Therapeutics (CRSP) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

CRISPR Therapeutics (CRSP) presented a strategic overview and portfolio highlights at the 43rd Annual J.P. Morgan Healthcare Conference. The company is focused on developing transformative gene-based medicines across four franchises, including the approved CASGEVY therapy, multiple clinical programs, and a strong financial position. They …

Cathie Wood's $362 Million CRISPR Therapeutics Bet Isn't Just Bold -- It's Backed by a Catalyst Many Investors Are Underrating

If you're keeping an eye on gene-editing specialist CRISPR Therapeutics (NASDAQ: CRSP), you probably already know the up-and-coming biopharmaceutical outfit is a favorite of Ark Investment Management's CEO and chief stock picker, Cathie Wood. As of the latest look, the company's holding nearly $270 …

Monashee Investment Management LLC Takes Position in CRISPR Therapeutics AG $CRSP

Monashee Investment Management LLC has initiated a new position in CRISPR Therapeutics AG (NASDAQ:CRSP) during the first quarter, acquiring 50,000 shares valued at approximately $2.38 million, representing 1.3% of its portfolio. This move comes as CRISPR Therapeutics' stock has recently traded down 1.9% at …

Crispr Therapeutics AG (CRSP) Receives a Hold from Goldman Sachs

Goldman Sachs has maintained a "Hold" rating on Crispr Therapeutics AG (CRSP) with a price target of $48.00, following the company's shares closing at $46.99. Despite a "Moderate Buy" consensus from other analysts with a higher average price target, Crispr Therapeutics reported a quarterly …

CRSP: CRISPR Therapeutics AG Latest Stock Price, Analysis, News and Trading Ideas

This article provides the latest stock information for CRISPR Therapeutics AG (CRSP), including its current stock price, market capitalization, volume, and recent performance. It also lists recent news articles related to CRSP and highlights popular discussions on other stocks like HIMS and SPY.

Ispire Technology stock initiated with buy rating at BTIG on ODM growth

BTIG has initiated coverage on Ispire Technology (NASDAQ: ISPR) with a buy rating and a price target of $3.50, citing the company's strong position in the nicotine ODM and OEM market. Despite a recent earnings miss, the firm believes Ispire is well-positioned to capture …

Enterprise value to EBITDA forward of Ispire Technology Inc. – NASDAQ:ISPR

This article focuses on the enterprise value to EBITDA (EV/EBITDA) forward metric for Ispire Technology Inc., trading under the NASDAQ:ISPR ticker. It appears to be a financial data point or analysis provided by a financial platform, showing the period, value, and change in this …

CRISPR Therapeutics AG $CRSP Shares Sold by Amova Asset Management Americas Inc.

Amova Asset Management Americas Inc. reduced its stake in CRISPR Therapeutics AG (NASDAQ:CRSP) by 5.3% in the first quarter, selling over 104,000 shares, though CRSP remains a significant holding for the firm. Simultaneously, other institutional investors like Hollencrest Capital Management and KBC Group NV …

CRISPR Therapeutics stock trades steady as gene-editing pipeline advances after quarterly loss narro

CRISPR Therapeutics stock remained steady as the company narrowed its quarterly losses and advanced its gene-editing pipeline, primarily focusing on sickle cell disease and oncology. The company's financial performance was bolstered by collaboration revenues, which helped offset high research and development costs. Investors are …

ISPR Q2 2026 Earnings: Significant EPS Miss Drives Stock Decline - Management Guidance Update

ISPR Q2 2026 Earnings: Significant EPS Miss Drives Stock Decline - Financial Health Score

Ispire Technology consolidates CEO leadership after executive shift

Ispire Technology Inc. has streamlined its top leadership by appointing Tuanfang Liu as the sole Chief Executive Officer, while Michael Wang transitioned to CEO of its North American subsidiary, Aspire North America. This change aims to consolidate executive decision-making and clarify responsibilities between the …